Communicators

ERFURT and BERLIN, Germany, June 5th, 2020 - AMP German Cannabis Group Inc. (“AMP” or the “Company”) (CSE: XCX) (FSE: C4T, ISIN: CA00176G1028) announces that The Office of Medical Cannabis (“OMC”), the government organization of the Netherlands for distribution of medical cannabis products, notified AMP that it has postponed selling EU-GMP medical cannabis to additional importers, including AMP, until further notice.

AMP has received all the required licenses to import irradiated cannabis flowers from the Dutch and German government authorities. During May, AMP placed its first order to import two Bedrocan International branded products from OMC, which subsequently confirmed receipt of AMP’s order.

In addition, the Company completed the audit of its supply chain to ensure the quality and integrity of the pharmaceutical goods is maintained during transportation, warehousing, handling, testing and distribution from foreign medical cannabis suppliers to distributors in Germany.

Dr. Stefan Feuerstein, Director and President of AMP, commented: “It is our understanding that German and Dutch government authorities are currently negotiating new export quotas for medical cannabis. AMP will be able to procure supply from the Netherlands once the OMC increases its production supply for export and supply restrictions are lifted. Independent from that, we are in very advanced negotiations with several foreign cannabis producers who already have an EU-GMP certification and are expecting to sign at least one definitive supply agreement within the next month. Our potential suppliers generally operate cultivation facilities with an annual production capacity between 5,000 and 10,000 kg.”

About AMP German Cannabis Group Inc.

AMP German Cannabis Group is licensed to import European Union - Good Manufacturing Practice (EU-GMP) medical cannabis and sell to pharmaceutical distributers or pharmacists directly, the only point-of-sale for medical cannabis to German patients.

AMP has entered into a non-exclusive distribution agreement for medical cannabis with a leading distributor of pharmaceuticals products to more than 13,000 pharmacies throughout Germany for monthly shipments starting in the second half of 2020.

AMP will begin importing from the Netherlands, Canada and other countries upon its medical cannabis suppliers receiving German EU-GMP certification. For more information, please visit: www.amp-eu.com.

Contact:

Mr. Alex Blodgett, CEO and Director

Telephone: +236-833-1602

Email: investor@amp-eu.com  

AMP social media links:

-          Twitter: https://twitter.com/AMP_Cannabis

-          LinkedIn: https://www.linkedin.com/company/ampgermancannabisgroup

-          Facebook: https://www.facebook.com/AMPGCG/

Media Kit: https://www.amp-eu.com/media-kit

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements that are based on the Company's expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business plans and milestones and the timing thereof. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.

SOURCE AMP German Cannabis Group Inc.